After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment ... or occupational dust. Also ...

After years of limited advancements in chronic obstructive pulmonary disease (COPD ... or occupational dust. Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees ...

Researchers are exploring how small airway abnormalities in younger smokers could help identify who is at risk of developing COPD and establish how the chronic lung disease progresses.

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

Regeneron has leveraged its monoclonal ... With the recent EU approval in chronic obstructive pulmonary disease, we now model $21 billion in peak Dupixent sales by 2029. While the partnership ...